TLP
TGTX icon

Tri Locum Partners’s TG Therapeutics TGTX Stock Holding History

Tri Locum Partners’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-288,462
Closed -$3.41M – 85
2022
Q4 		$3.41M Buy
+288,462
New +$2.09M 1.38% 26
2021
Q2 		– Sell
-148,620
Closed -$7.16M – 39
2021
Q1 		$7.16M Buy
148,620
+78,688
+113% +$3.78M 1.78% 15
2020
Q4 		$3.64M Buy
+69,932
New +$2.36M 1.32% 21

Other funds holding TGTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Tri Locum Partners's TGTX Position: Q1 2023 in Review

Tri Locum Partners sold out of TG Therapeutics (TGTX) in Q1 2023, closing a stake of 288,462 shares — an estimated $3.41M sold.

Tri Locum Partners first reported a position in TGTX in Q4 2020 and held it in 3 quarters. The position peaked at $7.16M in Q1 2021. 214 funds tracked by Wall St. Rank hold TGTX as of Q1 2023.

  • Tri Locum Partners reported no remaining TG Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Tri Locum Partners sold 288,462 TG Therapeutics shares in Q1 2023, an estimated $3.41M.
  • Tri Locum Partners first reported a position in TG Therapeutics in Q4 2020 and held it in 3 quarters.
  • Tri Locum Partners's TG Therapeutics position peaked at $7.16M in Q1 2021.
  • 214 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2023.

Based on Tri Locum Partners's 13F filing for Q1 2023, filed 15 May 2023.